Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2025)

Corvus Pharmaceuticals has reported Receivables over the past 4 years, most recently at $32000.0 for Q3 2025.

  • Quarterly results put Receivables at $32000.0 for Q3 2025, down 77.14% from a year ago — trailing twelve months through Sep 2025 was $32000.0 (down 77.14% YoY), and the annual figure for FY2024 was $75000.0, up 44.23%.
  • Receivables for Q3 2025 was $32000.0 at Corvus Pharmaceuticals, down from $86000.0 in the prior quarter.
  • Over the last five years, Receivables for CRVS hit a ceiling of $1.2 million in Q4 2022 and a floor of $11000.0 in Q3 2023.
  • Median Receivables over the past 4 years was $72500.0 (2024), compared with a mean of $177300.0.
  • Biggest five-year swings in Receivables: crashed 95.58% in 2023 and later soared 1172.73% in 2024.
  • Corvus Pharmaceuticals' Receivables stood at $1.2 million in 2022, then crashed by 95.58% to $52000.0 in 2023, then surged by 44.23% to $75000.0 in 2024, then tumbled by 57.33% to $32000.0 in 2025.
  • The last three reported values for Receivables were $32000.0 (Q3 2025), $86000.0 (Q2 2025), and $79000.0 (Q1 2025) per Business Quant data.